Viloxazine clinical trials
Also written SPN-812.
How each study uses Viloxazine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Viloxazine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 2 Apr 2021 · QELBREE · NDA 211964 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2017 (4)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2017 | 4 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test Viloxazine, phase 3 first.
- Dec 2026Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)Phase 3 · Supernus Pharmaceuticals, Inc.
Studies
Open first, then newest update. How each study uses Viloxazine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHDRecruitingPhase 4Supernus Pharmaceuticals, Inc.NCT04781140Written as 100mg SPN-812
- Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)Active, not recruitingPhase 3Supernus Pharmaceuticals, Inc.NCT02736656Written as SPN-812
- Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood SymptomsCompletedPhase 4Supernus Pharmaceuticals, Inc.NCT06185985Written as SPN-812
- Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating WomenCompletedPhase 4Supernus Pharmaceuticals, Inc.NCT06259331Written as SPN-812 (600mg, QD)
- Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHDCompletedPhase 4Supernus Pharmaceuticals, Inc.NCT04786990Written as SPN-812
- Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHDCompletedPhase 3Supernus Pharmaceuticals, Inc.NCT04143217Written as SPN-812
- Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHDCompletedPhase 3Supernus Pharmaceuticals, Inc.NCT04016779Written as SPN-812
- Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHDCompletedPhase 2Supernus Pharmaceuticals, Inc.NCT02633527Written as 100mg SPN-812
- Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHDCompletedPhase 3Supernus Pharmaceuticals, Inc.NCT03247543Written as 200mg SPN-812
- Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHDCompletedPhase 3Supernus Pharmaceuticals, Inc.NCT03247530Written as 100mg SPN-812
- Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHDCompletedPhase 3Supernus Pharmaceuticals, Inc.NCT03247556Written as 400mg SPN-812
- Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHDCompletedPhase 3Supernus Pharmaceuticals, Inc.NCT03247517Written as 200mg SPN-812
- Classroom Study of SPN-812 in Children With ADHDWithdrawnPhase 3Supernus Pharmaceuticals, Inc.NCT04016792Written as 200 mg SPN-812
Codes
What other systems call Viloxazine · ClinicalTrials.gg INT008406
- MeSH (NLM) D014745ViloxazineConfirmed NLM, Wikidata
- UNII (FDA) 5I5Y2789ZFVILOXAZINEConfirmed FDA, NLM, Wikidata
- RxNorm 11196Confirmed FDA, Wikidata
- Wikidata Q907148viloxazineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152877ViloxazineOne source FDA
- DrugBank DB09185One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D014745 | Viloxazine | Confirmed NLM, Wikidata |
| UNII (FDA) | 5I5Y2789ZF | VILOXAZINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 11196 | — | Confirmed FDA, Wikidata |
| Wikidata | Q907148 | viloxazine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152877 | Viloxazine | One source FDA |
| DrugBank | DB09185 | — | One source Wikidata |
Also registered as viloxazine hydrochloride (UNII OQW30I1332 · RxNorm 142143).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.